# Acurion

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/acurion

- Industry: Healthcare IT
- Headquarters: San Diego, US
- Website: www.acurionhealth.com
- Total disclosed funding: $4.3M
- Latest round: Seed (Mar 17, 2026)
- Investors on record: 4

## About

Acurion, Inc. is a US-based company focused on precision oncology solutions, utilizing advanced algorithms to enhance cancer biomarker identification and facilitate timely access to precision therapies for patients.Founded in 2021 in San Diego, US, Acurion, Inc. specializes in precision oncology solutions. The company has secured USD 4.3 mn in Seed funding led by TK & Partners, with participation from Bootstrap Ventures, Mesa Verde Venture Partners, and others. Acurion has completed a total of 1 deal, with its most recent funding round occurring on March 17, 2026, bringing the total amount raised to USD 4.3 mn and the current company valuation to USD 15.47 mn.Acurion specializes in precision oncology solutions with its core product, OncoGaze™, a workflow that leverages advanced algorithms to predict clinically actionable genomic biomarkers from routine digital histological tissue slides. This innovative tool uncovers morphological patterns that are often undetectable by the human eye, thereby significantly accelerating the biomarker screening process. OncoGaze™ provides rapid genomic test results within seconds, facilitating timely access to life-saving precision therapies for patients with cancer. Acurion primarily serves healthcare providers, oncologists, and research institutions across various geographical markets, including North America and Europe, focusing on enhancing patient care through immediate and optimal treatment solutions.Acurion generates revenue through a subscription-based model, facilitating partnerships with healthcare institutions and oncology practices that utilize its OncoGaze™ platform. Clients pay a recurring fee to access the software and associated services, ensuring ongoing support and updates. Specific pricing plans for the OncoGaze™ platform are determined based on the scale of deployment and the needs of the client, tailoring services to fit both small clinics and larger healthcare systems.In March 2026, Acurion, Inc. raised USD 4.3 mn in Seed funding to support the commercialization and further development of its clinical validation. The company aims to launch additional products designed to enhance its OncoGaze™ platform, targeting expansion within North America and Europe by 2027.

## Funding rounds

- Seed, Mar 17, 2026, $4.3M — Mesa Verde Venture Partners, National Foundation for Cancer Research, Bootstrap Ventures, TK & Partners

## Investors

- Mesa Verde Venture Partners (https://capitalatlas.ai/funds/mesa-verde-venture-partners) — Seed
- National Foundation for Cancer Research — Seed
- Bootstrap Ventures (https://capitalatlas.ai/funds/bootstrap-ventures) — Seed
- TK & Partners (https://capitalatlas.ai/funds/tk-partners) — Seed